Authorized Generics Noose Tightens With “Best Price” Proposal, FTC Study
Executive Summary
The Federal Trade Commission's decision to study the practice of authorized generics could become moot if the marketing of such products by brand companies becomes financially unattractive due to a potential change in Medicaid "best price" reporting requirements
You may also be interested in...
Authorized Generics: FTC Study May Get Jumpstart; PhRMA Paper Finds No Harm
The Federal Trade Commission's study on the impact of authorized generics could be enhanced under an amendment to the legislation reauthorizing the FDA's Rx user fee program
Authorized Generics: FTC Study May Get Jumpstart; PhRMA Paper Finds No Harm
The Federal Trade Commission's study on the impact of authorized generics could be enhanced under an amendment to the legislation reauthorizing the FDA's Rx user fee program
FTC Commissioner Urges Generic Firms To Shun Reverse Payment Deals
The generic industry should refrain from entering into settlement agreements with brand companies that involve payments to keep generics off the market, Federal Trade Commissioner Jon Leibowitz said at the Generic Pharmaceutical Association's Annual Policy Conference in Washington, D.C. Sept. 19